Markets:

Overview

News

Currencies

International

Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

91.00 +0.39 (+0.43%)

Streaming Delayed Price Updated: 10:04 AM EST, Dec 19, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2

...

29 30 31 32 33 34 35 36 37

...

74 75 Next >

Facebook News To Shut Down In Europe, Warner Bros. Discovery Revises Outlook As Strike Bites, Manchester United No Longer Up For Sale: Today's Top Stories ↗

September 05, 2023

Benzinga Why Facebook News is Shutting Down in Europe: What It Means for Users?

Via Benzinga

Legal Twist In Drug Price Negotiation: Federal Judge Quits Case Amid Allegations Of Stock Ownership ↗

September 05, 2023

On Friday, Judge Thomas Rose, serving in the U.S.

Via Benzinga

8 Pharma Stocks Affected by New Drug Price Negotiation Rules ↗

September 02, 2023

Which companies have the most to lose now that Medicare can negotiate directly with them on the prices of some of the most widely used drugs?

Via The Motley Fool

Is This Underfollowed Genetic Diagnostics Stock a Buy for Growth Investors? ↗

September 02, 2023

The genetic test maker is rapidly increasing test volumes.

Via The Motley Fool

P/E Ratio Insights for AstraZeneca ↗

August 08, 2023

Via Benzinga

AstraZeneca Plc (AZN) Q2 2023 Earnings Call Transcript ↗

July 28, 2023

AZN earnings call for the period ending June 30, 2023.

Via The Motley Fool

Biden Administration Vs. Big Pharma: What the Legal Showdown Means for Your Wallet ↗

August 31, 2023

The Biden administration's move to lower drug prices has prompted a flurry of legal challenges.

Via Benzinga

Ambrx Biopharma Has Surged 483% This Year. But It Could Just Be Getting Started. ↗

August 31, 2023

The company has another update on its prostate cancer program that could further prod shares.

Via Investor's Business Daily

What Impact Will Medicare Price Negotiations Have on Big Pharma Stocks? ↗

August 29, 2023

Investors appear to be yawning for the most part at the latest news on Medicare drug price negotiations.

Via The Motley Fool

Biden Targets Cancer, Diabetes Drugs In Controversial Medicare Price Battle ↗

August 29, 2023

The Centers for Medicare and Medicaid Services unveiled the first ten drugs subject to price negotiations under President Joe Biden's Inflation Reduction Act, including:

Via Benzinga

Blockbusters From AbbVie, Merck, Lilly Highlight List Of 10 Drugs Subject To Price Cuts ↗

August 29, 2023

The Biden administration is planning to negotiate the prices of 10 drugs in 2026.

Via Investor's Business Daily

Beaten Down COVID-19 Vaccine Partner Stock Catalent Finalizes Deal With Activist Investor, Reports Mixed Q4 Earnings ↗

August 29, 2023

Catalent Inc (NYSE: CTLT), valued at around $8 billion, has finalized a deal with activist investor Elliott Investment Management.

Via Benzinga

Pharma Giants Unite Against Drug Price Negotiation: AstraZeneca Latest To Challenge The Government ↗

August 25, 2023

AstraZeneca Plc (NASDAQ: AZN) announced its legal challenge against the U.S.

Via Benzinga

Untapped Potential: 3 Stocks Tackling the Toughest Rare Diseases ↗

August 25, 2023

Treating rare diseases is a tough but potentially lucrative business. With clinical trials coming due, here are three stocks to buy.

Via InvestorPlace

AstraZeneca urges re-examination of unintended consequences of Inflation Reduction Act on American cancer and rare disease patients

August 25, 2023

From AstraZeneca

Via Business Wire

Boeing's 737 Deliveries Delay Due To Supplier Spirit Aerosystems, Petco Health and Wellness Stock Tumbles, AstraZeneca Under Legal Lens: Today's Top Stories ↗

August 24, 2023

Benzinga

Via Benzinga

Topics Supply Chain

AstraZeneca Under Legal Lens, Faces Two COVID-19 Vaccine Lawsuits In London ↗

August 24, 2023

AstraZeneca Plc (NASDAQ: AZN), the Anglo-Swedish pharmaceutical giant, is reportedly under legal scrutiny as it faces two lawsuits related to its

Via Benzinga

Topics Lawsuit

GRI Bio Is Bringing Hope To Patients With Idiopathic Pulmonary Fibrosis And Lupus ↗

August 24, 2023

Inflammatory diseases are chronic conditions that involve the abnormal activation of the body's immune system, leading to chronic inflammation in various organs and tissues. Two of these diseases that...

Via Benzinga

3 Sorry Pharma Stocks to Sell in August Before It’s Too Late ↗

August 22, 2023

Factors in the marketplace caused these companies to underperform, making them some of the top pharma stocks to sell.

Via InvestorPlace

FDA Greenlights Pfizer's RSV Vaccine: Moms Can Now Protect Babies Before Birth ↗

August 22, 2023

Monday, the FDA approved Pfizer Inc's (NYSE: PFE) Abrysvo (Respiratory Syncytial Virus Vaccine), the company's bivalent RSV prefusion F (RSVpreF) vaccine, to prevent the infection in infants from birth...

Via Benzinga

The 3 Most Undervalued Pharma Stocks to Buy Now: August 2023 ↗

August 21, 2023

These are the pharma stocks to buy at undervalued levels as they represent companies investing heavily in research and development.

Via InvestorPlace

AstraZeneca Data at WCLC Advance Ambition to Have an AstraZeneca Medicine for More Than Half of All Patients Treated for Lung Cancer by 2030

August 16, 2023

From AstraZeneca

Via Business Wire

Cheaper Alternatives of Weight-Loss Drugs? Chinese Pharma Companies Are Working On a Local Version ↗

August 16, 2023

Chinese pharma firms are reportedly working on producing local equivalents of advanced weight-loss medications, challenging Western pharmaceutical giants in a

Via Benzinga

Week In Review: BeiGene And Bristol-Myers Squibb Close BeiGene-Celgene PD-1 Partnership ↗

August 12, 2023

BeiGene and Bristol-Myers Squibb have formally completed the breakup of the BeiGene-Celgene partnership, returning 23.3 million ordinary BeiGene shares to BeiGene. Meanwhile, Gracell Biotechnologies...

Via Talk Markets

Is This Blue Chip Dividend Stock a Buy for Growth Investors? ↗

August 08, 2023

The British drugmaker has been a winner for shareholders in recent years.

Via The Motley Fool

Week In Review: Mundipharma Considers $1 Billion Sale Of China Operations ↗

August 05, 2023

Mundipharma is considering selling its China operations in a deal that could be worth $1 billion. Additionally, Oramed Pharma plans to form a $60 million JV with Hefei Tianhui Biotech to commercialize...

Via Talk Markets

BioMedNewsBreaks – Genprex Inc.’s (NASDAQ: GNPX) Third Fast Track Designation Validates REQORSA(R)’s Potential

August 04, 2023

Via Investor Brand Network

Analyst Upgrades Ionis Pharmaceuticals To Buy Amid Key Pipeline Developments: Eplontersen And Donidalorsen Show Promising Outlook ↗

July 31, 2023

Citi analyst upgraded Ionis Pharmaceuticals Inc (NASDAQ: IONS) from Neutral to Buy with a price target of $60, increased from $36, citing multiple key

Via Benzinga

3 Pharma Stocks to Buy for Their Promising Progress ↗

July 31, 2023

Explore the top promising pharma stocks, leading the proverbial marathon towards transformative healthcare.

Via InvestorPlace

AstraZeneca Abandons Blood Cancer, Cardiovascular Programs Amid Portfolio Prioritization ↗

July 28, 2023

Earlier today, AstraZeneca plc (NASDAQ: AZN)

Via Benzinga

< Previous 1 2

...

29 30 31 32 33 34 35 36 37

...

74 75 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.